|  |  |
| --- | --- |
| Name: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ | Date: \_\_\_\_\_\_\_\_\_\_\_\_\_\_ |

IV Therapy

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 1 |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  | 2 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  | 3 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| 4 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  | 5 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 6 |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  | 7 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 8 |  |  |  |  |  | 9 |  |  |  |  |  |  |  |  |
|  |  |  |  |  | 10 |  |  |  |  |  |  |  |  |  |  |  | 11 |  |  |  |  |  |  | 12 |  |  |  |  |  |
|  |  |  | 13 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 14 |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  | 15 |  |  |  | 16 |  |  |  |  |  |  |  |  |  | 17 |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  | 18 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  | 19 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  | 20 |  |  |  |  |  |  |  |  |  | 21 | 22 |  |  |  |  | 23 |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 24 |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  | 25 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  | 26 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  | 27 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |

|  |  |
| --- | --- |
| **Across****3.** The amount of pressure needed to draw a solvent across a membrane**5.** An isotonic solution that contains Na, Cl, K, Ca, and lactate**13.** gtts/mL; 10, 15, 20, and 60 are most common**14.** A potential complication of IV therapy; may be in the form of air, blood clot, or catheter**16.** Movement of water across a semipermeable membrane from an area of lower concentration of particles to an area of greater concentration**17.** The total number of solute particles in a unit weight of solvent; Normal is approximately 285 mOsm/kg**18.** A potential complication of IV therapy that can occur if an IV push dose of a medication is administered too rapidly**19.** A type of IV solution capable of freely crossing capillary walls; administration results in quick, but short-term, plasma expansion; clear solutions that do not contain protein**20.** The rupturing of a cell; can result from rapid or over-administration of hypotonic solutions**21.** The primary chemical component within the body; accounts for 50-70% of adult body weight**23.** Tonicity of this type of IV fluid is greater than that of body fluids; administration results in fluid shifts out of the cell and into the intravascular space**25.** A common bacterial source of cellulitis**26.** If peripheral IV access cannot be obtained in an emergency situation, this type of access should be attempted immediately**27.** KVO | **Down****1.** Another term for osmolality, this can be thought of as a solution's "pulling power"; isotonic, hypotonic, or hypertonic**2.** Tonicity of this type of IV fluid is the same as that of body fluids; these fluids expand intravascular space without causing fluid shifts**4.** Fluid in plasma (intravascular space) and interstitial spaces; constitutes approximately 1/4 to 1/3 of total body fluid**6.** Fluid within the cells; constitutes approximately 2/3 to 3/4 of total body fluid**7.** A common cause of pain related to IV therapy; may be caused by administration of irritating or cold IV fluids**8.** The only IV fluid compatible with blood transfusions**9.** The concentration of solute particles contained in a unit volume of solvent; Normal range is 275 mOsm/L to 295 mOsm/L**10.** COLLOIDS / A type of IV solution with particles too large to pass through semipermeable membranes; contain proteins, carbohydrates, and lipids; usually have a cloudy appearance**11.** The tonicity of 5% Dextrose in Water (D5W) once the solution is infused and the dextrose is metabolized**12.** Symptoms of this complication include acute dyspnea, moist rales, bounding pulses, hypertension, and JVD**15.** A patient receiving 5% Dextrose in Water (D5W) is at risk for developing this condition as potassium shifts from ECF to ICF during cellular use of glucose**22.** A colloid that is derived from human blood**24.** Tonicity of this type of IV fluid is lower than that of body fluids; administration results in fluid shifts from the intravascular space into the intracellular and interstitial spaces |